CureVac Returns Full Rights To mRNA Ornithine Transcarbamylase Deficiency Treatment To Arcturus Therapeutics.

February 12, 2019

Fierce Biotech (2/11, Taylor) reports “CureVac has dropped mRNA ornithine transcarbamylase (OTC) deficiency treatment ARCT-810,” returning “full rights to the candidate to Arcturus Therapeutics, which plans to file an IND by the end of the year.” The arti...